Tag: Nubeqa

Home / Nubeqa

Categories

Darolutamide is approved by the USFDA for metastatic castration-sensitive prostate cancer

On June 3, 2025, the Food and Drug Administration (FDA) sanctioned darolutamide (Nubeqa, Bayer Healthcare Pharmaceuticals Inc.) for metastatic castration-sensitive prostate cancer (mCSPC). The FDA has...
nubeqa

Darolutamide tablets is approved by FDA for metastatic hormone-sensitive prostate cancer

August 2022: Darolutamide (Nubeqa, Bayer HealthCare Pharmaceuticals Inc.) tablets combined with docetaxel were approved by the Food and Drug Administration for adult patients with metastatic hormone-...
nubeqa

Scan the code